- Home
- KINS vs VTYX Comparison
KINS vs VTYX Comparison
Compare KINS & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- VTYX
- Stock Information
- Founded
- KINS 1886
- VTYX 2018
- Country
- KINS United States
- VTYX United States
- Employees
- KINS N/A
- VTYX N/A
- Industry
- KINS Property-Casualty Insurers
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- KINS Finance
- VTYX Health Care
- Exchange
- KINS Nasdaq
- VTYX Nasdaq
- Market Cap
- KINS 197.1M
- VTYX 184.6M
- IPO Year
- KINS N/A
- VTYX 2021
- Fundamental
- Price
- KINS $17.69
- VTYX $2.30
- Analyst Decision
- KINS Strong Buy
- VTYX Buy
- Analyst Count
- KINS 1
- VTYX 5
- Target Price
- KINS $6.50
- VTYX $8.40
- AVG Volume (30 Days)
- KINS 419.0K
- VTYX 2.3M
- Earning Date
- KINS 11-12-2024
- VTYX 11-07-2024
- Dividend Yield
- KINS N/A
- VTYX N/A
- EPS Growth
- KINS N/A
- VTYX N/A
- EPS
- KINS 1.34
- VTYX N/A
- Revenue
- KINS $149,645,312.00
- VTYX N/A
- Revenue This Year
- KINS N/A
- VTYX N/A
- Revenue Next Year
- KINS $15.56
- VTYX N/A
- P/E Ratio
- KINS $13.25
- VTYX N/A
- Revenue Growth
- KINS 3.44
- VTYX N/A
- 52 Week Low
- KINS $1.95
- VTYX $1.67
- 52 Week High
- KINS $18.08
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- KINS 61.96
- VTYX 47.68
- Support Level
- KINS $15.06
- VTYX $2.21
- Resistance Level
- KINS $16.83
- VTYX $2.54
- Average True Range (ATR)
- KINS 1.21
- VTYX 0.27
- MACD
- KINS -0.15
- VTYX -0.05
- Stochastic Oscillator
- KINS 62.93
- VTYX 8.02
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.